Objective: The extent to which adverse cognitive effects (ACEs) to a specific antiepileptic drug (AED) affect the chance of developing ACEs to other AEDs (i.e., cross-sensitivity) is unknown. We investigated the rates of cross-sensitivity of ACEs among AEDs and examined the association between clinical characteristics and occurrence of having ACEs to multiple AEDs in adults with epilepsy.
Methods: The rates of cross-sensitivity of intolerable ACEs (IACEs; i.e., ACEs leading to dosage reduction or discontinuation) and the non-AED predictors of IACEs were investigated in 2269 patients who had taken at least two AEDs at a single center. We accounted for AED load and looked for specific cross-sensitivities between AEDs as well as cross-sensitivity based on the AED mechanism of action.
Results: Among the 2269 patients, the highest rates of IACEs were seen with TPM (26.3%), ZNS (9.8%), PHT (8.8%), and VPA (8.5%). Intolerable ACEs to two or more AEDs occurred in 100 patients (4.4%). History of psychiatric condition(s) and absence seizure type were independent predictors of IACEs to two or more AEDs. High rates of cross-sensitivity of IACEs were seen between phenytoin (PHT) and lamotrigine (LTG), valproate (VPA) and phenytoin, and valproate and zonisamide (ZNS). For example, of patients who had IACEs to VPA and were also prescribed ZNS, 46.2% had IACEs to ZNS (abbreviated as VPA→ZNS: 46.2%); of patients who had IACEs to ZNS and were also prescribed VPA, 37.5% had IACEs to VPA (abbreviated as ZNS→VPA: 37.5%). Other results are as follows: LTG→PHT: 28.6%, PHT→LTG: 20.0%, PHT→VPA: 42.9%, and VPA→PHT: 27.3%. No specific cross-sensitivities were found among AEDs sharing a similar mechanism of action.
Significance: The probability of ACE intolerability to an AED can increase if a patient developed ACE intolerability to another AED. The cross-sensitivity rates for ACE intolerability between LTG and PHT, PHT and VPA, and VPA and ZNS were found to be particularly high. The cross-sensitivity rates provided here may be clinically useful for predicting ACE intolerability in patients taking certain AEDs and for AED selection in individual patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.yebeh.2015.03.020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Renal Denervation as a Novel Therapeutic Approach for Resistant Hypertension: Mechanisms, Efficacy and Future Directions.
High Blood Press Cardiovasc Prev
November 2024
Department of Pharmacology, Therapeutics and Toxicology, Faculty of Basic Medical Sciences, University of Lagos, Lagos, Nigeria.
Article Synopsis
- Resistant hypertension occurs when patients have high blood pressure that doesn't respond to standard medications like beta-blockers and diuretics, leading to serious health risks such as stroke and heart failure.
- Renal denervation (RDN) is an invasive procedure introduced as an alternative treatment for those with resistant hypertension, showing promise in terms of safety and short-term benefits, but with potential long-term complications like renal stenosis.
- Further research is needed to explore RDN's effectiveness, develop tailored treatment strategies, and identify biomarkers that can predict outcomes for patients undergoing this procedure.
Hydrolyzed protein formula improves the nutritional tolerance by increasing intestinal development and altering cecal microbiota in low-birth-weight piglets.
Front Nutr
October 2024
Laboratory of Animal Nutritional Physiology and Metabolic Process, Key Laboratory of Agro-ecological Processes in Subtropical Region, Institute of Subtropical Agriculture, Chinese Academy of Sciences, Changsha, Hunan, China.
Background: Prematurity or low birth weight (LBW), poses a significant challenge in global health. Exploring appropriate and effective nutritional interventions is crucial for the growth and development of LBW infants. Hydrolyzed protein formula has been suggested as a potential solution to prevent intestinal dysfunction and improve digestion and absorption in infants.
View Article and Find Full Text PDFHypothyroidism.
Lancet
October 2024
Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
Article Synopsis
- Hypothyroidism is a widespread condition characterized by a deficiency of thyroid hormone, leading to symptoms like fatigue, weight gain, and cold intolerance, but often requiring biochemical tests for diagnosis.
- The most common cause is autoimmune thyroiditis (Hashimoto's), although other factors like certain medications and surgeries can also lead to the condition.
- Levothyroxine is the primary treatment, effective in many cases, but some patients continue to experience symptoms or abnormal thyroid-stimulating hormone levels, prompting discussion on treatment approaches and thresholds.
Cost-effectiveness of ace inhibitors versus ARBs in heart failure management.
Medicine (Baltimore)
September 2024
University College Hospital, Ibadan, Nigeria.
Article Synopsis
- Heart failure is a major global health issue, and managing it effectively is crucial for improving patient outcomes and lowering healthcare costs, with ACE inhibitors and ARBs being common treatments.
- A study using a decision-analytic Markov model aimed to compare the cost-effectiveness of ACE inhibitors and ARBs, considering medical costs and health outcomes for patients with heart failure.
- Results indicated that ACE inhibitors had lower costs and slightly better health outcomes (quality-adjusted life years) compared to ARBs, with the findings remaining consistent across various sensitivity and subgroup analyses.
Sodium Intake and Incident Atrial Fibrillation in Individuals With Vascular Disease.
JAMA Netw Open
July 2024
Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
Importance: Numerous prospective cohort studies have reported a J-shaped association of urinary sodium excretion with cardiovascular events and mortality.
Objective: To study the association between sodium intake and incident atrial fibrillation (AF).
Design, Setting, And Participants: This cohort study included participants in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) and Telmisartan Randomised Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (TRANSCEND) multicenter, randomized clinical trials comparing the effect of ramipril 10 mg daily with telmisartan 80 mg daily, or their combination (ONTARGET) or 80 mg telmisartan daily with placebo (TRANSCEND) for the outcome of death from cardiovascular causes, myocardial infarction, stroke, or hospitalization for heart failure.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!